CI 1044
Alternative Names: PD 189659Latest Information Update: 16 Feb 2006
At a glance
- Originator Pfizer
- Class Anti-inflammatories; Antiasthmatics; Azepines; Nicotinic acids; Small molecules
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Asthma; Chronic obstructive pulmonary disease
Most Recent Events
- 16 Feb 2006 No development reported - Preclinical for Chronic obstructive pulmonary disease in France (PO)
- 10 Feb 2005 No development reported - Phase-I for Asthma in France (PO)
- 10 Feb 2005 No development reported - Phase-I for Asthma in USA (PO)